Literature DB >> 1675219

Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity.

J L Liesveld1, K E Frediani, J M Winslow, R E Duerst, C N Abboud.   

Abstract

Mononuclear phagocytes participate in host immunological defense against tumors. We have investigated the role of selected recombinant cytokines on human macrophage-mediated tumor cytotoxicity in vitro utilizing a human colon cancer cell line target, SW1116, and murine monoclonal antibody 17-1A. Blood monocytes were kept in continuous culture to allow differentiation into macrophages. Maximum antibody dependent cellular cytotoxicity (ADCC) as measured in a 3H-thymidine release assay occurred after culturing the monocytes for 5-7 days. Human recombinant macrophage colony stimulating factor (CSF) (1,000 U/ml) did not increase ADCC above control levels whereas recombinant human granulocyte-macrophage colony stimulating factor, interleukin 4, and interleukin 3 were all capable of increasing ADCC. Antibodies to the CD11/CD18 integrin receptors did not significantly inhibit ADCC. When the ADCC incubation occurred in the presence of antibodies to the human Fc receptors, ADCC was inhibited significantly only by anti-FcRIII (3G8). A role for tumor necrosis factor alpha or other soluble mediators of cytotoxicity was not demonstrable in this system. These studies suggest avenues for manipulation and augmentation of macrophage-mediated antitumor ADCC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675219     DOI: 10.1002/jcb.240450412

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

Review 1.  Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumors.

Authors:  P Ragnhammar
Journal:  Med Oncol       Date:  1996-09       Impact factor: 3.064

2.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

3.  Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.

Authors:  Jonathan W Friedberg; Jennifer L Kelly; Donna Neuberg; Derick R Peterson; Jeffery L Kutok; Rabih Salloum; Thomas Brenn; David C Fisher; Elizabeth Ronan; Virginia Dalton; Lynn Rich; Diana Marquis; Paul Sims; Paul G Rothberg; Jane Liesveld; Richard I Fisher; Robert Coffman; Tim Mosmann; Arnold S Freedman
Journal:  Br J Haematol       Date:  2009-06-10       Impact factor: 6.998

4.  Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients.

Authors:  Y C Cheng; V Valero; M L Davis; M C Green; A M Gonzalez-Angulo; R L Theriault; J L Murray; G N Hortobagyi; N T Ueno
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

5.  Modulation of colony stimulating factor release and apoptosis in human colon cancer cells by anticancer drugs.

Authors:  S Calatayud; T D Warner; J A Mitchell
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

6.  The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas.

Authors:  M P Velders; C M van Rhijn; E Oskam; G J Fleuren; S O Warnaar; S V Litvinov
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

7.  CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes.

Authors:  Wei Hseun Yeap; Kok Loon Wong; Noriko Shimasaki; Esmeralda Chi Yuan Teo; Jeffrey Kim Siang Quek; Hao Xiang Yong; Colin Phipps Diong; Antonio Bertoletti; Yeh Ching Linn; Siew Cheng Wong
Journal:  Sci Rep       Date:  2016-09-27       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.